Maro Ohanian

Cancer statistics, 2022

Cancer statistics, 2023

Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso

FLT3 inhibitors in acute myeloid leukemia

Atypical hemolytic uremic syndrome

Cancer statistics, 2020

Cancer statistics, 2024

Cancer Statistics, 2021

Non-Transgenic Mouse Models of Kidney Disease

Critical appraisal of eculizumab for atypical hemolytic uremic syndrome

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies

Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Delivery technologies for cancer immunotherapy

Management of hemolytic uremic syndrome

The JAK/STAT signaling pathway: from bench to clinic

Targeting apoptosis in cancer therapy

Natural product-based nanoformulations for cancer therapy: Opportunities and challenges

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

The promise of Janus kinase inhibitors in the treatment of hematological malignancies

Immune checkpoint inhibitors: recent progress and potential biomarkers

Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive Agents

Typical and Atypical Hemolytic Uremic Syndrome in the Critically Ill

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

SMAC mimetics as potential cancer therapeutics in myeloid malignancies

Atypical Hemolytic Uremic Syndrome: A Meta‐Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens

Efficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic Leukemia

Liposomal Formulations in Clinical Use: An Updated Review

Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems

Toward the potential cure of leukemias in the next decade

Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas

Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome

The role of clofarabine in acute myeloid leukemia

Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase

Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin’s lymphomas

Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia

Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS)

Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report

Interleukin‐7 receptor‐α gene mutations are not detected in adult T‐cell acute lymphoblastic leukemia

Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial

LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial

Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia

Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML